AUS
NZ
UK
CA
USA
IND
Analysts tracking Futura Medical PLC (LSE:FUM) have revised and notably increased their revenue forecasts following the company's better-than-anticipated interim results. The sexual healthcare company achieved a maiden profit ahead of schedule, prompting these updates.
According to the latest projections, analysts now estimate that Futura’s revenue for the current year will be approximately £13.4 million, with expectations rising to £18.6 million for 2025. This is a significant upward revision from previous forecasts made by Trinity Delta (TD), which had predicted revenues of £9.2 million and £15.1 million for the next two financial years, respectively.
The key driver behind these revised forecasts is the anticipated U.S. launch of Eroxon, Futura's fast-acting erectile dysfunction gel. This product is set to become the only over-the-counter erectile dysfunction treatment available in the United States, positioning it with a substantial competitive advantage in the market.
TD highlighted that the revenue upgrades are largely attributed to the earlier-than-expected U.S. launch and the associated milestones projected for both years. However, the research house also noted the challenges in forecasting revenue due to the unpredictable nature of product launches, such as channel fill and stocking effects, as well as limited disclosure from partners regarding deal terms and milestone details.
In light of these developments, TD has adjusted its net present value estimate for Futura Medical from £371 million to £392 million, translating to a projected share price of 130p. This marks a significant increase from the stock’s closing price of 37p on Wednesday.
The revisions reflect heightened confidence in the company’s future revenue prospects and the potential impact of Eroxon’s U.S. debut on its financial performance. As the company progresses with its launch and establishes its market presence, further updates to forecasts and valuations may follow.
